So far, CD56+ γδT cells and their functions have mainly been investigated in the aspect of anti-tumor activity, as CD56+ γδT cells show much stronger cytotoxicity following stimulation with IL-2 and IL-12 than CD56− γδT cells (57). The gene discussed is NCAM1; the disease is neoplasm.